FDA Advisory Committee Recommends Approval of Shire ’s Prucalopride (SHP555) for Chronic Idiopathic Constipation

Cambridge, Mass. – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted unanimously (10 to 0) that the risk-benefit profile of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news